

Zealand Pharma A/S

29/09/2016	
Healthcare	
	Book Building Zealand Pharma A/S (ZEAL DC, ISIN DK0060257814) Augmentation de capital
	 Taille de l'Offre : environ 5 % du capital représentant l'équivalent de 18m USD Les actions nouvelles seront émises sous un code ISIN temporaire DK0060759835 et seront fusionnées avec le code ISIN existant le 06/10. Cours de clôture : 102 DKK
	 Prix des nouvelles actions émises : décote de 0% à 5% sur le cours de clôture Utilisation des fonds : Essais cliniques, R&D, financement de la croissance
	Ouverture du book : 29/09 après clôture à Copenhague Clôture du book : Dans la soirée du 29/09
	 Aucun frais de courtage pour l'acheteur Date de la transaction : 30/09. Règlement / Livraison en J+2 (04/10) réalisé par Bryan, Garnier & Co
	Bryan, Garnier & Co intervient en qualité de Coordinateur Global Unique et Seul Teneur de Livres
	Book Building Zealand Pharma A/S (ZEAL DC, ISIN DK0060257814) Capital increase
	 Deal size : approximately 5% of outstanding shares representing the equivalent of USD18m
	 The new shares will be issued under a temporary ISIN code DK0060759835, and will be merged with the existing ISIN code on 06/10 post admission. Stock price at close : 102 DKK
	 Issue price of new shares: discount of 0% to 5% to the close Use of proceeds : Clinical studies, R&D, general corporate purposes
	 Book opening : 29/09 after Copenhagen market close Book will be closed overnight on the 29/09
	 No commission for Buyers Trade date: 30/09. Settlements done by Bryan, Garnier & Co at T+2, 04/10
	Bryan, Garnier & Co is acting as Sole Global Coordinator and Sole Bookrunner



London	Paris	New York	Munich
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	
Authorised and regulated by the	Financial Conduct Authority (FCA)		
Financial Conduct Authority (FCA)	and the Autorité de Contrôle		
	prudential et de resolution (ACPR)		

Important information

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This report has been prepared solely for informational purposes and is intended only for use by the designated recipient(s).

This report is non-independent research within the meaning of the FCA rules. This report is not being held out as an objective or independent explanation of the matters contained within it and has been sent to you for marketing purposes only and should not be treated as such. This report has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. Bryan Garnier & Co Limited is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This information was obtained from sources we believe to be reliable, but its accuracy is not guaranteed. All information is subject to change without notice. This does not constitute a solicitation or offer to buy or sell securities or any other instruments, or a recommendation with respect to any security or instrument mentioned herein. This is not a confirmation of terms of any transaction. No representations are made herein with respect to availability, pricing, or performance. Additional information available on request.

This document should only be read by those persons to whom it is addressed and is not intended to be relied upon by any person without subsequent written confirmation of its contents. If you have received this e-mail message in error, please destroy it and delete it from your computer. Any form of reproduction, dissemination, copying, disclosure, modification, distribution and/or publication of this e-mail message is strictly prohibited. Please note that any views or opinions presented in this e-mail are solely those of the author and do not necessarily represent those of Bryan Garnier & Co Limited.

Finally, the recipient should check this e-mail and any attachments for the presence of viruses. Bryan Garnier & Co Limited accepts no liability for any damage caused by any virus transmitted by this email.